Efficacy And SafetyUpdated results from the Phase I/II SPOTLIGHT study of briquilimab in patients with CIndU show promising efficacy and safety after a single SC dose, assessed for 12 weeks and followed by a 24-week safety observation.
Market OpportunityAbsence of competitive pressure from major competitors in the CIndU market could create an attractive commercial opportunity for JSPR.
Product ProfileBriquilimab demonstrates a superior response rate compared to Barzolvolimab in its trial, highlighting its strong profile.